Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors.

MLA

Janka, Eszter Anna, et al. “Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors.” Cancers, vol. 16, no. 17, Sept. 2024, p. 2981. EBSCOhost, https://doi.org/10.3390/cancers16172981.

APA

Janka, E. A., Szabó, I. L., Kollár, S., Toka-Farkas, T., Ványai, B., Várvölgyi, T., Kapitány, A., Shabu, H., Szegedi, A., & Emri, G. (2024). Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors. Cancers, 16(17), 2981. https://doi.org/10.3390/cancers16172981

Chicago

Janka, Eszter Anna, Imre Lőrinc Szabó, Sándor Kollár, Tünde Toka-Farkas, Beatrix Ványai, Tünde Várvölgyi, Anikó Kapitány, Hibah Shabu, Andrea Szegedi, and Gabriella Emri. 2024. “Prognostic Role of Clinicopathological Characteristics and Serum Markers in Metastatic Melanoma Patients Treated with BRAF and MEK Inhibitors.” Cancers 16 (17): 2981. doi:10.3390/cancers16172981.